Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Mar 3:1:28-34.
doi: 10.1016/j.plabm.2015.02.001. eCollection 2015 Apr 1.

A practical approach for the validation and clinical implementation of a high-sensitivity cardiac troponin I assay across a North American city

Peter A Kavsak  1   2   3 , John Beattie  3   4 , Robin Pickersgill  3   5 , Lynn Ford  3   6 , Nadia Caruso  3   4 , Lorna Clark  2   3
Affiliations

A practical approach for the validation and clinical implementation of a high-sensitivity cardiac troponin I assay across a North American city

Peter A Kavsak et al. Pract Lab Med. .

Abstract

Objectives: Despite several publications on the analytical performance of high-sensitivity cardiac troponin (hs-cTn) assays, there has been little information on how laboratories should validate and implement these assays into clinical service. Our study provides a practical approach for the validation and implementation of a hs-cTn assay across a large North American City.

Design and methods: Validation for the Abbott ARCHITECT hs-cTnI assay (across 5 analyzers) consisted of verification of limit of blank (LoB), precision (i.e., coefficient of variation; CV) testing at the reported limit of detection (LoD) and within and outside the 99th percentile, linearity testing, cTnI versus hs-cTnI patient comparison within and between analyzers (Passing and Bablok and non-parametric analyses). Education, clinical communications, and memorandums were issued in advance to inform all staff across the city as well as a selected reminder the day before live-date to important users. All hospitals switched to the hs-cTnI assay concurrently (the contemporary cTnI assay removed) with laboratory staff instructed to repeat samples previously measured with the contemporary cTnI assay with the hs-cTnI assay only by physician request.

Results: Across the 5 analyzers and 6 reagent packs the overall LoB was 0.6 ng/L (n=60) with a CV of 33% at an overall mean of 1.2 ng/L (n=60; reported LoD=1.0 ng/L), with linearity demonstrated from 45,005 ng/L to 1.1 ng/L. Precision testing with a normal patient-pool QC material (mean range across 5 analyzers was 3.9-4.4 ng/L) yielded a range of CVs from 7% to 10% (within-run) and CVs from 7% to 18% (between-run) with the high patient-pool QC material (mean range across 5 analyzers was 29.6-36.3 ng/L) yielding a range of CVs from 2% to 5% (within-run) and CVs from 4% to 8% (between-run). There was agreement between hs-cTnI versus cTnI with the patient samples (slope ranges: 0.89-1.03; intercept ranges: 1.9-3.8 ng/L), however, the median CV on patient samples <100 ng/L across the analyzers was 5.6% for hs-cTnI versus 18.7% for the contemporary assay (p<0.001). Following the switch to hs-cTnI testing, no requests for repeat measurements were received.

Conclusions: Validation and implementation of hs-cTnI testing across multiple sites requires collaboration within the laboratories and between hospital laboratories and clinical staff.

Keywords: High-sensitivity cardiac troponin; Implementation; Multicenter; Quality; Validation.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Linear regression analysis for the serial dilutions for the hs-cTnI assay.
Fig. 2
Fig. 2
Passing and Bablok regression analyses on the average concentrations of 40 EDTA patient-pool plasma samples (range: 1.6–7016 ng/L) between hs-cTnI and cTnI.
Fig. 3
Fig. 3
Precision profile for hs-cTnI and cTnI with patient-pool EDTA plasma samples with concentrations <100 ng/L.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kavsak P.A. Early standardization of high sensitivity troponin T reporting – a lost opportunity. Clin Biochem. 2011;44:758–759. - PubMed
    1. High-sensitivity cardiac troponin for the rapid diagnosis of acute coronary syndrome in the emergency department: a clinical and cost-effectiveness evaluation [Internet]. Source: Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; March 2013. 〈http://www.cadth.ca/en/products/optimal-use/ high-sensitivity-troponin〉. - PubMed
    1. Kavsak P.A., Jaffe A.S., Hickman P.E., Mills N.L., Humphries K.H., McRae A. Canadian Institutes of Health Research dissemination grant on high-sensitivity cardiac troponin. Clin Biochem. 2014;47:155–157. - PubMed
    1. Kavsak P.A., Allen L.C., Apple F.S., Booth R.A., Chan P.C., Delvin E. Cardiac troponin testing in the acute care setting: ordering, reporting, and high sensitivity assays—an update from the Canadian society of clinical chemists (CSCC) Clin Biochem. 2011;44:1273–1277. - PubMed
    1. Apple F.S., Collinson P.O., IFCC Task Force on Clinical Applications of Cardiac Biomarkers Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem. 2012;58:54–61. - PubMed